Andrew Ko, MD

Colorectal and gastrointestinal cancer specialist

Dr. Andrew H. Ko is a specialist in colorectal and gastrointestinal cancer, with a particular interest in pancreatic cancer. Ko is interested in the development of new treatment strategies, including molecularly targeted therapies, for patients with colorectal and gastrointestinal malignancies.

He earned an undergraduate degree in applied mathematics and biology at Brown University in Providence, R.I., and a medical degree at Johns Hopkins School of Medicine in Baltimore, Md. After an internship and residency at Beth Israel Hospital in Boston, he completed a fellowship in medical oncology at Stanford University before joining UCSF Medical Center in 2001.

Clinics

Gastrointestinal Medical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Patient Information and Appointments: (415) 353-9888
Administrative Inquiries: (415) 476-3270
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Conditions & Treatments

Board Certification

Medical Oncology, American Board of Internal Medicine

Academic Title

Professor

More about Andrew Ko

Education

Johns Hopkins University 1995

Residencies

Beth Israel Hospital-Boston, MA, Internal Medicine 1998

Fellowships

Stanford University Medical Center 2001

Selected Research and Publications

  1. Ko AH. Shifting the treatment model for resectable pancreatic cancer. Lancet Gastroenterol Hepatol. 2018 Jun; 3(6):375-376.
  2. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 Mar 15.
  3. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 Apr 01; 36(10):1020-1044.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.